Sanofi to test dengue vaccine in India

Sanofi Pasteur will begin trials of its dengue vaccine in India. The trial will involve 120 adults and results should be made available by 2013. If all goes according to the set timeline, a vaccine will be available by 2015, the Times of India reports. "Sites for the vaccine's final trials will stretch from Thailand to India as this vaccine has to work on populations across countries," Sanofi ($SNY) CEO Chris Viehbacher told the news outlet. The company experienced a setback with the vaccine in September when study results showed the drug was only 30% effective against dengue fever type 2, far below the anticipated 70% efficacy rate. Story

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.